AR132189A1 - Método para la producción de preparados de partículas de aav recombinantes - Google Patents

Método para la producción de preparados de partículas de aav recombinantes

Info

Publication number
AR132189A1
AR132189A1 ARP240100694A ARP240100694A AR132189A1 AR 132189 A1 AR132189 A1 AR 132189A1 AR P240100694 A ARP240100694 A AR P240100694A AR P240100694 A ARP240100694 A AR P240100694A AR 132189 A1 AR132189 A1 AR 132189A1
Authority
AR
Argentina
Prior art keywords
adeno
gene
raavp
culturing
associated virus
Prior art date
Application number
ARP240100694A
Other languages
English (en)
Inventor
Julia Emmenecker
Sven Markert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR132189A1 publication Critical patent/AR132189A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C12N7/025—Packaging cell lines, e.g. transcomplementing cell lines, for production of virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se informa un método para producir un preparado de partículas virales adenoasociadas recombinantes (rAAVp) que comprende la etapa de cultivar una célula de mamífero que comprende casetes de expresión para un gen viral no adenoasociado, que está interespaciado entre dos repeticiones terminales invertidas (ITR) de AAV, un gen rep de virus adenoasociado, un gen cap de virus adenoasociado, un gen E1A de virus adenoasociado, un gen E1B de virus adenoasociado, un gen E2A de virus adenoasociado, un E4orf6 de virus adenoasociado y un gen ARN VA de virus adenoasociado, y producir así el rAAVp, en donde el cultivo es a un valor de pH en el rango de y que incluye pH 7,4 a pH 7,6. El rendimiento del rAAVp producido mediante el cultivo a un valor de pH en el rango de y que incluye pH 7,4 a pH 7,6 es mayor que el rendimiento de un rAAVp producido mediante un cultivo a un valor de pH en el rango de y que incluye pH 7,0 a pH 7,2 y el rAAVp producido mediante el cultivo a un valor de pH en el rango de y que incluye pH 7,4 a pH 7,6 tiene un porcentaje mayor de partículas completas que un rAAVp producido mediante un cultivo a un valor de pH en el rango de y que incluye pH 7,0 a pH 7,2.
ARP240100694A 2023-03-21 2024-03-21 Método para la producción de preparados de partículas de aav recombinantes AR132189A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP23163162 2023-03-21

Publications (1)

Publication Number Publication Date
AR132189A1 true AR132189A1 (es) 2025-06-04

Family

ID=85724795

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100694A AR132189A1 (es) 2023-03-21 2024-03-21 Método para la producción de preparados de partículas de aav recombinantes

Country Status (11)

Country Link
US (1) US20260139234A1 (es)
EP (1) EP4683676A1 (es)
JP (1) JP2026511015A (es)
KR (1) KR20250162543A (es)
CN (1) CN120835797A (es)
AR (1) AR132189A1 (es)
AU (1) AU2024239386A1 (es)
IL (1) IL323167A (es)
MX (1) MX2025010665A (es)
TW (1) TW202503065A (es)
WO (1) WO2024194280A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026085229A1 (en) * 2024-10-16 2026-04-23 Genzyme Corporation Methods and compositions for raav production

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6100242A (en) 1995-02-28 2000-08-08 The Regents Of The University Of California Gene therapies for enhancing cardiac function
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
WO2000014205A2 (en) 1998-09-04 2000-03-16 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant aav vectors
CA2995542A1 (en) 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えaavビリオン調製物を生成するための方法
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
EP2529020B1 (en) 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
EP3795581A3 (en) 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
JP6342886B2 (ja) 2012-04-18 2018-06-13 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia Aavカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法
NZ716102A (en) 2013-07-22 2021-12-24 The Children’S Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
EP3384015A4 (en) 2015-12-01 2019-05-29 Spark Therapeutics, Inc. SCALABLE PROCESS FOR THE PREPARATION OF A RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR IN A SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR THE CLINICAL APPLICATION
WO2018226887A1 (en) 2017-06-07 2018-12-13 Spark Therapeutics, Inc. ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION
EP3658250A4 (en) 2017-06-30 2021-10-27 Spark Therapeutics, Inc. AAV VECTOR COLUMN CLEANING PROCEDURE
EP4585229A3 (en) 2017-11-08 2026-01-14 Novartis AG Means and method for preparing viral vectors and uses of same

Also Published As

Publication number Publication date
MX2025010665A (es) 2025-10-01
KR20250162543A (ko) 2025-11-18
IL323167A (en) 2025-11-01
WO2024194280A1 (en) 2024-09-26
TW202503065A (zh) 2025-01-16
AU2024239386A1 (en) 2025-08-14
EP4683676A1 (en) 2026-01-28
CN120835797A (zh) 2025-10-24
JP2026511015A (ja) 2026-04-10
US20260139234A1 (en) 2026-05-21

Similar Documents

Publication Publication Date Title
Aponte-Ubillus et al. Molecular design for recombinant adeno-associated virus (rAAV) vector production
AU2023200992B2 (en) Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use
US12466858B2 (en) Helper plasmid and method for preparing recombinant adeno-associated virus
US20190321463A1 (en) Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
Qiao et al. Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes
CN115997006A (zh) 用于产生aav的双双功能载体
JP2022507534A5 (es)
MX2025010665A (es) Metodo para la produccion de preparaciones de particulas virales adenoasociadas (aav) recombinantes
JP2009195237A5 (es)
WO2022116285A1 (zh) 一种重组腺相关病毒的制备方法、系统及重组杆粒
Wang et al. A robust system for production of superabundant VP1 recombinant AAV vectors
Yamaji et al. Efficient production of Japanese encephalitis virus-like particles by recombinant lepidopteran insect cells
Wang et al. Establishment of a scalable manufacturing platform for in-silico-derived ancestral adeno-associated virus vectors
US20100323429A1 (en) Methods for purifying baculovirus
Zhang et al. Improvement of protein production by engineering a novel antiapoptotic baculovirus vector to suppress the expression of Sf‐caspase‐1 and Tn‐caspase‐1
AR123777A1 (es) Constructos de ácido nucleico para transcripción de arn va
Keith et al. Screening of transformed insect cell lines for recombinant protein production
MX2024002379A (es) Cápsides y vectores de aav modificados.
TWI510625B (zh) 至少可感染三種昆蟲宿主之雜合桿狀病毒及其用途
JP2023546116A5 (es)
WO2025209979A1 (en) METHOD FOR PRODUCING RECOMBINANT VIRUSES OR VIRUS-LIKE PARTICLES (VLPs) IN MAMMALIAN CELL LINES
MX2024009778A (es) Producción de virus de la estomatitis vesicular recombinante de alto título en cultivo celular en suspensión
Huang et al. Homologous recombination risk in baculovirus expression vector system
Pei et al. Enhancement of exogenous protein stability in AcMNPV by overexpressing lef5 gene during passaging
RU2025128274A (ru) Способ получения препаратов частиц рекомбинантного aav